Publication:
The glycosylation site of myelin oligodendrocyte glycoprotein affects autoantibody recognition in a large proportion of patients

dc.contributor.coauthorFernandez, Iris Marti
dc.contributor.coauthorMacrini, Caterina
dc.contributor.coauthorKrumbholz, Markus
dc.contributor.coauthorHensbergen, Paul J.
dc.contributor.coauthorEderveen, Agnes L. Hipgrave
dc.contributor.coauthorWinklmeier, Stephan
dc.contributor.coauthorKurne, Aslı
dc.contributor.coauthorJenne, Dieter
dc.contributor.coauthorKamp, Frits
dc.contributor.coauthorGerdes, Lisa Ann
dc.contributor.coauthorHohlfeld, Reinhard
dc.contributor.coauthorWuhrer, Manfred
dc.contributor.coauthorKuempfel, Tania
dc.contributor.coauthorMeinl, Edgar
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorVural, Atay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:39:07Z
dc.date.issued2019
dc.description.abstractAutoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of patients with inflammatory demyelination and are detected with MOG-transfected cells. While the prototype anti-MOG mAb 8-18C5 and polyclonal anti-MOG responses from different mouse strains largely recognize the FG loop of MOG, the human anti-MOG response is more heterogeneous and human MOG-Abs recognizing different epitopes were found to be pathogenic. The aim of this study was to get further insight into details of antigen-recognition by human MOG-Abs focusing on the impact of glycosylation. MOG has one known N-glycosylation site at N31 located in the BC loop linking two beta-sheets. We compared the reactivity to wild type MOG with that toward two different mutants in which the neutral asparagine of N31 was mutated to negatively charged aspartate or to the neutral alanine. We found that around 60% of all patients (16/27) showed an altered reactivity to one or both of the mutations. We noted seven different patterns of recognition of the two glycosylation-deficient mutants by different patients. The introduced negative charge at N31 enhanced recognition in some, but reduced recognition in other patients. In 7/27 patients the neutral glycosylation-deficient mutant was recognized stronger. The folding of the extracellular domain of MOG with the formation of beta-sheets did not depend on its glycosylation as seen by circular dichroism. We determined the glycan structure of MOG produced in HEK cells by mass spectrometry. The most abundant glycoforms of MOG expressed in HEK cells are diantennary, contain a core fucose, an antennary fucose, and are decorated with alpha 2,6 linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified. Together, we (1) increase the knowledge about heterogeneity of human autoantibodies to MOG, (2) show that the BC loop affects recognition in about 60% of the patients, (3) report that all patients recognized the unglycosylated protein backbone, while (4) in about 20% of the patients the attached sugar reduces autoantibody binding presumably via steric hindrance. Thus, a neutral glycosylation-deficient mutant of MOG might enhance the sensitivity to identify MOG-Abs.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuEU - TÜBİTAK
dc.description.sponsorshipGerman Research Foundation (DFG)
dc.description.sponsorshipMunich Cluster for Systems Neurology
dc.description.sponsorshipClinical Competence Network
dc.description.sponsorshipWerner Reichenberger Stiftung
dc.description.sponsorshipVerein zur Therapieforschung fur Multiple Sklerose-Kranke
dc.description.sponsorshipEuropean Academy of Neurology
dc.description.sponsorshipAlexander von Humboldt Foundation Georg Forster Research Fellowship Program
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TÜBİTAK) (Scientific and Technological Research Council of Turkey (TÜBİTAK))- BIDEP
dc.description.sponsorshipEuropean Union's Horizon 2020 Research and Innovation Program
dc.description.sponsorshipHorizon 2020
dc.description.sponsorshipEuropean Union (European Union)
dc.description.versionPublisher version
dc.description.volume10
dc.identifier.doi10.3389/fimmu.2019.01189
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR01684
dc.identifier.issn1664-3224
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85068908532
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2052
dc.identifier.wos470995000001
dc.keywordsImmunology
dc.keywordsMyelin oligodendrocyte glycoprotein (MOG)
dc.keywordsGlycosylation
dc.keywordsAutoantibody recognition
dc.keywordsMass-spectrometry
dc.keywordsDemyelination
dc.language.isoeng
dc.publisherFrontiers
dc.relation.grantnoSFB TR128
dc.relation.grantnoExC 1010 SyNergy
dc.relation.grantno668036, RELENT
dc.relation.grantno2219
dc.relation.ispartofFrontiers in Immunology
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8339
dc.subjectMedicine
dc.subjectNeurology
dc.titleThe glycosylation site of myelin oligodendrocyte glycoprotein affects autoantibody recognition in a large proportion of patients
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorVural, Atay
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
8339.pdf
Size:
664.65 KB
Format:
Adobe Portable Document Format